Show simple item record

dc.contributor.authorSablerolles, Roos S G
dc.contributor.authorGoorhuis, Abraham
dc.contributor.authorGeurtsvanKessel, Corine H
dc.contributor.authorde Vries, Rory D
dc.contributor.authorHuckriede, Anke L W
dc.contributor.authorKoopmans, Marion P G
dc.contributor.authorLafeber, Melvin
dc.contributor.authorPostma, Douwe F
dc.contributor.authorvan Baarle, Debbie
dc.contributor.authorVisser, Leo G
dc.contributor.authorDalm, Virgil A S H
dc.contributor.authorKootstra, Neeltje A
dc.contributor.authorRietdijk, Wim J R
dc.contributor.authorvan der Kuy, P Hugo M
dc.date.accessioned2021-11-11T09:57:51Z
dc.date.available2021-11-11T09:57:51Z
dc.date.issued2021-09-24
dc.identifier.pmid34691071
dc.identifier.doi10.3389/fimmu.2021.753319
dc.identifier.urihttp://hdl.handle.net/10029/625359
dc.language.isoenen_US
dc.subjectAd26.Cov2.Sen_US
dc.subjectBNT162.b2en_US
dc.subjectCOVID-19en_US
dc.subjectHeterologous vaccine regimenen_US
dc.subjectHomologous vaccination regimenen_US
dc.subjectSARS-CoV-2en_US
dc.subjectmRNA1273en_US
dc.subjectrandomized clinical trialen_US
dc.titleHeterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.en_US
dc.typeArticleen_US
dc.identifier.eissn1664-3224
dc.identifier.journalFrontiers in immunology 2021;12:753319en_US
dc.source.journaltitleFrontiers in immunology
dc.source.volume12
dc.source.beginpage753319
dc.source.endpage
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record